Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Arteries of the Lower Limbs01:24

Arteries of the Lower Limbs

181
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
181
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

150
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
150
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

29
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
29
Seizures: Classification01:13

Seizures: Classification

309
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
309
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

300
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
300
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

315
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
315

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

How epilepsy risks might be introduced and discussed in clinical consultations.

Patient education and counseling·2025
Same author

Top Ten epilepsy research priorities: A UK priority setting partnership.

Seizure·2025
Same author

Invitation to participate in a prospective case-control study of sudden unexpected death in epilepsy.

Epilepsia·2021
Same author

Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial.

Lancet (London, England)·2020
Same author

Valproate risk form-Surveying 215 clinicians involving 4775 encounters.

Acta neurologica Scandinavica·2020
Same author

Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus.

The New England journal of medicine·2019

Related Experiment Video

Updated: Jun 14, 2025

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

17.7K

Why have status epilepticus trials failed: Wrong drugs or wrong trials?

Hannah Cock1

  • 1City St George's, University of London, School of Health and Medical Sciences, Neurosciences Clinical Academic Group, Cranmer Terrace, London SW17 0RE, UK.

Epilepsy & Behavior : E&B
|September 1, 2024
PubMed
Summary

Despite decades of research, clinical trial outcomes for status epilepticus remain poor. This review examines reasons for trial failures and suggests improvements in trial design and regulatory frameworks for better results.

Keywords:
Antiseizure medicationsClinical TrialsOutcomesStatus EpilepticusTrial design

More Related Videos

Long-term Continuous EEG Monitoring in Small Rodent Models of Human Disease Using the Epoch Wireless Transmitter System
08:43

Long-term Continuous EEG Monitoring in Small Rodent Models of Human Disease Using the Epoch Wireless Transmitter System

Published on: July 21, 2015

25.6K
Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy
04:51

Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy

Published on: April 11, 2019

9.4K

Related Experiment Videos

Last Updated: Jun 14, 2025

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

17.7K
Long-term Continuous EEG Monitoring in Small Rodent Models of Human Disease Using the Epoch Wireless Transmitter System
08:43

Long-term Continuous EEG Monitoring in Small Rodent Models of Human Disease Using the Epoch Wireless Transmitter System

Published on: July 21, 2015

25.6K
Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy
04:51

Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy

Published on: April 11, 2019

9.4K

Area of Science:

  • Neurology
  • Clinical Trials
  • Epilepsy Research

Background:

  • Status epilepticus (SE) research has seen increased interest over the past 20 years.
  • Despite this, patient outcomes have not improved, and several high-profile trials have failed.
  • Reasons for these failures are multifaceted and require careful consideration.

Purpose of the Study:

  • To discuss the various reasons behind the failure of status epilepticus clinical trials.
  • To review the importance of interpreting trial results within the broader scientific context.
  • To examine potential improvements in trial design, regulatory frameworks, and the use of artificial intelligence.

Main Methods:

  • Review of recent well-designed, adequately powered studies in established SE.
  • Analysis of studies in refractory and super-refractory SE.
  • Consideration of lessons learned from other disease areas, including COVID-19 RECOVERY trials.

Main Results:

  • Established SE trials, though failing primary endpoints, are influencing clinical practice.
  • Trials in refractory and super-refractory SE have yet to yield successful outcomes.
  • Significant financial and human costs are associated with unsuccessful SE trials.

Conclusions:

  • Interpreting trial results requires considering broader literature, safety, and practical aspects.
  • There is a critical need to review regulatory frameworks and adapt trial designs for SE.
  • Artificial intelligence tools may offer potential for future trial optimization.